|Bid||75.09 x 1800|
|Ask||0.00 x 1200|
|Day's Range||74.99 - 75.80|
|52 Week Range||61.01 - 82.27|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||22.49|
|Forward Dividend & Yield||0.66 (0.87%)|
|1y Target Est||N/A|
Agilent Technologies Inc. (NYSE:A) today announced that Saeed Hassanpour, Ph.D., has received the 2019 Agilent Early Career Professor Award (AECPA). Dr. Hassanpour is a member at the Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) and an associate professor in the Departments of Biomedical Data Science and Epidemiology at the Geisel School of Medicine at Dartmouth College, with an adjunct appointment in Computer Science.
Agilent Technologies, Inc. (NYSE:A) today announced the opening of a new state-of-the-art facility for spectroscopy research and development at the Harwell Science and Innovation Campus in Oxfordshire, UK. A leader in molecular spectroscopy, the new Agilent site will be a major research and development hub for laser spectroscopy. It will also incorporate Agilent’s Raman spectroscopy business, formerly known as Cobalt Light Systems (acquired by Agilent in 2017).
Agilent Technologies, Inc. (NYSE:A) today announced that for the fifth year in a row, the company has been named the industry leader in the Life Sciences Tools and Services category of the 2019 Dow Jones Sustainability Index (DJSI). “Agilent’s mission – to improve the quality of life – is the north star for our business, and we’re pleased the Dow Jones Sustainability Index recognizes our accomplishments across a wide range of sustainability measures,” said Mike McMullen, Agilent president and CEO.
Agilent Technologies Inc. today announced that the National Medical Products Administration has approved its PD-L1 IHC 22C3 pharmDx assay for use in China.
Agilent Technologies Inc. (NYSE:A) announced today that Professor Hualiang Jiang has received an Agilent Thought Leader Award. Professor Jiang directs the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and is a leading researcher in the area of medicinal chemistry and computational drug design.
Agilent Technologies, Inc. (NYSE:A) today announced that a quarterly dividend of 16.4 cents per share of common stock will be paid on Oct. 23, 2019 to all shareholders of record as of the close of business on Oct. 1, 2019. Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Agilent Technologies, Inc. (NYSE:A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $500 million. The offering is being conducted under an automatic shelf registration statement on file with the Securities and Exchange Commission. The estimated net proceeds of the offering are expected to be approximately $492.8 million.
Agilent Technologies Inc. (NYSE:A) today introduced its first new product from recently acquired ACEA Biosciences, at the 34th Congress of the International Society for Advancement of Cytometry, CYTO 2019 Congress, being held June 22–26, 2019 in Vancouver, Canada. The Agilent NovoCyte Advanteon Flow Cytometer is now one of the most sensitive cell analyzers available on the market. Flow cytometers are integral to basic research, drug discovery, and clinical diagnostics.
Agilent Technologies Inc. (NYSE:A) today announced the opening of a production facility in Colorado that more than doubles its capacity to develop and manufacture “oligos,” which are short DNA and RNA molecules that customers use to produce nucleic acid-based therapeutics. Agilent expects the demand for therapeutic oligo manufacturing to grow near 10% each year through 2025, to over $750 million by 2025. This facility will enable Agilent to meet this growing demand and to continue being a partner of choice to pharmaceutical and biotech companies.
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA®
Agilent Technologies Inc. (NYSE:A) announced today the results of its first Pharma Lab Leaders Survey looking to gather insights from pharmaceutical, biopharmaceutical, and contract research laboratories in seven countries around the world. Respondents included 650 laboratory managers, directors, and supervisors from China, Germany, India, South Korea, Switzerland, Austria, and the United States. “We were extremely pleased that Agilent wanted to work with us again to explore the challenges and opportunities within this unique group of laboratories,” said Paljit Sohal, principal consultant, of Frost & Sullivan.
Agilent Technologies Inc. (NYSE:A) introduced the newest member of its LC/MS portfolio today at the American Society for Mass Spectrometry Conference (ASMS) which is being held June 2 through June 6 in Atlanta, Georgia. The new Agilent InfinityLab LC/MSD iQ System incorporates ‘designed-in’ smart features, software, and hardware developed specifically for chemists and chromatographers who will benefit from the intuitive design and greater level of detail generated by a mass selective detector. An early maintenance feedback feature allows lab managers to plan routine maintenance on the lab’s schedule resulting in a focus on overall productivity.